Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - Neuphoria's lead drug candidate, BNC-210, is designed for the treatment of social anxiety disorder and post-traumatic stress disorder, offering rapid relief without common side effects [3] Company Overview - Neuphoria is advancing BNC-210, a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor [3] - The drug aims to restore neurotransmitter balance and is characterized as a well-tolerated, broad-spectrum anti-anxiety therapeutic [3] - The company has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease and other CNS conditions [3] Upcoming Events - The presentation by Spyros Papapetropoulos, M.D., Ph.D., will be available on demand starting September 5, 2025 [2] - The webcast can be accessed through the "Events" page in the investors section of Neuphoria's website [2]